Reliable manufacturing you can count on for your patients

A pegfilgrastim biosimilar proudly manufactured in the USA.

The facility
The US drug substance manufacturing facility was purposefully designed to produce PEGylated filgrastim and is compliant with current Good Manufacturing Practice (cGMP) standards.
The process
Manufacturing of UDENYCA® has demonstrated a high level of consistency across production campaigns.
The product
Since launch, over 550,000 syringes have been introduced to the supply chain.*1

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) suggest pegfilgrastim use to support clinical outcomes during chemotherapy.†2

See the guidelines

Receive occasional emails to learn more about UDENYCA®, reimbursement, and support services for your chemotherapy patients.

Sign up now

*January 2019 through December 2020.

Other suggestions for therapy are included in the NCCN Guidelines®.

References: 1. Data on file. Coherus BioSciences, Inc.; 2023. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Growth Factors V.1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed April 27, 2023. To view the most recent and complete version of the guidelines, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.